Hydroxychloroquine - What Goes On? | Page 15 | Australian Frequent Flyer
Australian Frequent Flyer

Welcome to Australia's leading independent Frequent Flyer and Travel Resource since 1998!
Our site contains tons of information that will improve your travel experience.

Joining AFF is fast, simple & absolutely free - register now and take immediate advantage of these great BENEFITS.

Once registered, this box will disappear. And you will see fewer advertisements :)

Login Now to remove this and all advertisements (GOLD and SILVER members)
Not a member? Register Now for free

Hydroxychloroquine - What Goes On?

tgh

Established Member
Joined
Apr 23, 2006
Messages
2,029
These news medias only spread negativity and stress.. They do no good to the humanity except giving more stress and anxiety which are extremely bad for immunity.

Indeed : Ignorance is Bliss... :)
 

lovetravellingoz

Senior Member
Joined
Jul 13, 2006
Messages
7,150
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

In this large multinational real-world analysis, we did not observe any benefit of hydroxychloroquine or chloroquine (when used alone or in combination with a macrolide) on in-hospital outcomes, when initiated early after diagnosis of COVID-19. Each of the drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.
....

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents
..
96 032 patients
...

Interpretation
We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.







An analysis of 96,000 patients shows those treated with hydroxychloroquine were also more likely to suffer irregular heart rhythms

A study of 96,000 hospitalized coronavirus patients on six continents found that those who received an antimalarial drug promoted by President Trump as a “game changer” in the fight against the virus had a significantly higher risk of death compared with those who did not.

People treated with hydroxychloroquine, or the closely related drug chloroquine, were also more likely to develop a type of irregular heart rhythm, or arrhythmia, that can lead to sudden cardiac death, it concluded.

The study, published Friday in the medical journal Lancet is the largest analysis to date of the risks and benefits of treating covid-19 patients with antimalarial drugs. Like earlier smaller studies, it delivered disappointing news to a world eager for promising treatments for the novel coronavirus as the global death toll grows to more than 300,000. While doctors have refined how they treat the disease, they have yet to discover a magic bullet against a pathogen for which humans have no known immunity.


 

andye

Established Member
Joined
Jan 14, 2013
Messages
3,887
Virgin
Platinum
Flights
My Map
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

In this large multinational real-world analysis, we did not observe any benefit of hydroxychloroquine or chloroquine (when used alone or in combination with a macrolide) on in-hospital outcomes, when initiated early after diagnosis of COVID-19. Each of the drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.
....

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents
..
96 032 patients
...

Interpretation
We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.







An analysis of 96,000 patients shows those treated with hydroxychloroquine were also more likely to suffer irregular heart rhythms

A study of 96,000 hospitalized coronavirus patients on six continents found that those who received an antimalarial drug promoted by President Trump as a “game changer” in the fight against the virus had a significantly higher risk of death compared with those who did not.

People treated with hydroxychloroquine, or the closely related drug chloroquine, were also more likely to develop a type of irregular heart rhythm, or arrhythmia, that can lead to sudden cardiac death, it concluded.

The study, published Friday in the medical journal Lancet is the largest analysis to date of the risks and benefits of treating covid-19 patients with antimalarial drugs. Like earlier smaller studies, it delivered disappointing news to a world eager for promising treatments for the novel coronavirus as the global death toll grows to more than 300,000. While doctors have refined how they treat the disease, they have yet to discover a magic bullet against a pathogen for which humans have no known immunity.


Note that this is not a randomised study
Although it reports adjustment for confounding varaiables, it is difficult to adjust with accuracy
You could certainly argue that sicker patients are more likely to be given drugs
It would be very surprising if there was a big positive effect of antimalarials though
 

drron

Enthusiast
Joined
Jul 4, 2002
Messages
22,165
Though the campaign against Hydroxychloroquine is not over.From the results the Use of Hydroxychloroquine with Azithromycin shouldn't continue as in the studies the use of either alone is just as effective with less risk of side effects.certainly the cardiac side effects were not unexpected as both drugs increase the risk of ventricular arrhythmias.In the 60 + years experience using hydroxychloroquine it has been found that at a dose of 400mg a day there is much reduced risk of heart complications and the virtual elimination of the most serious eye complications.Some of the studies had higher doses than 400mg per day..

As well there are now several reports of hydroxychloroquine with zinc gives better results-note these are no trials.But one from NY.
"The study looked at the records of 932 COVID-19 patients treated at local hospitals with hydroxychloroquine and azithromycin.
More than 400 of them were also given 100 milligrams of zinc daily.
Researchers said the patients given zinc were one and a half times more likely to recover, decreasing their need for intensive care."


And evidence why zinc may be effective with hydroxychloroquine.

As well better results when Hydroxychloroquine is used as prophylaxis.

Now taking it as prophylaxis doesn't mean you won't get Covid but it seems to reduce the chances.A large trial underway now in Detroit.ironically being run by Cardiologists.

It is also being used in countries such as Algeria and Honduras as treatment of mild cases.The reports are they are less likely to go on to severe disease and ventilation-which is what those countries wanted due to not having the facilities for managing many such cases.Again not official trials.
 

drron

Enthusiast
Joined
Jul 4, 2002
Messages
22,165
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

In this large multinational real-world analysis, we did not observe any benefit of hydroxychloroquine or chloroquine (when used alone or in combination with a macrolide) on in-hospital outcomes, when initiated early after diagnosis of COVID-19. Each of the drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.
....

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents
..
96 032 patients
...

Interpretation
We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.







An analysis of 96,000 patients shows those treated with hydroxychloroquine were also more likely to suffer irregular heart rhythms

A study of 96,000 hospitalized coronavirus patients on six continents found that those who received an antimalarial drug promoted by President Trump as a “game changer” in the fight against the virus had a significantly higher risk of death compared with those who did not.

People treated with hydroxychloroquine, or the closely related drug chloroquine, were also more likely to develop a type of irregular heart rhythm, or arrhythmia, that can lead to sudden cardiac death, it concluded.

The study, published Friday in the medical journal Lancet is the largest analysis to date of the risks and benefits of treating covid-19 patients with antimalarial drugs. Like earlier smaller studies, it delivered disappointing news to a world eager for promising treatments for the novel coronavirus as the global death toll grows to more than 300,000. While doctors have refined how they treat the disease, they have yet to discover a magic bullet against a pathogen for which humans have no known immunity.


This article is now being queried.It seems totally unreliable.here is one of the reasons.
"5. Data from Australia are not compatible with government reports (too many cases for just five hospitals, more in-hospital deaths than had occurred in the entire country during the study period). Surgisphere (the data company) have since stated this was an error of classification of one hospital from Asia. This indicates the need for further error checking throughout the database. "
So more people have died of using hydroxychloroquine for treating Covid than have died in the whole of Australia for covid.
 

RooFlyer

Enthusiast
Joined
Nov 12, 2012
Messages
15,914
Qantas
Platinum
Flights
My Map
Medical journal has concerns about data behind key hydroxychloroquine study (ABC)

Edit - just realised this is the same thing as drron posted on. Behind the play, I and the ABC are ...

Well, well, well. A Lancet publication, no less. 'Peer reviewed' no less (I've posted a number of times how "peer reviewed" is used by many to imply "this is correct" or "you can't challenge this" - a review by peers who simply agree with your theory or perspective isn't much of a review. Some editors will choose reviewers with a fair idea beforehand of whether they will pan or pass an article submitted to them. I have had a number of first hand experiences in the scientific press :) ).

Anyway ... hold the press on hydroxychloroquine

Original bolding:

A UK medical journal that published an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients says it has concerns about the data behind the study.

The observational study published in The Lancet in late May looked at 96,000 hospitalised COVID-19 patients who were treated with the malaria drug that US President Donald Trump claims he takes and has urged others to use.

Several clinical trials were put on hold after the study was published.

The study, using data provided by healthcare data analytics firm Surgisphere, was not a traditional clinical trial that would have compared hydroxychloroquine to a placebo or other medicine.

Today, the journal said "serious scientific questions" had been brought to its attention about the validity of the data behind the study.

... 150 doctors signed an open letter to the journal calling the article's conclusions into question and asking The Lancet to publish the peer review comments.
 
Last edited:

drron

Enthusiast
Joined
Jul 4, 2002
Messages
22,165
An encouraging report of a drug used for a lymphoma and chronic lymphocytic leukaemia having a good response used in Sick Covid 19 patients.only a small study though.
 

ethernet

Active Member
Joined
Aug 10, 2006
Messages
700
Which of the 3 strains by four categories, then by age groups?
It is accepted there are 3 strains I think we know HCQ is no good for severe/ICU levels, and at that level immnosuppression is the go. Why do a study before a risk/reward cost benefit analysis has been done? In nursing homes - that seems reasonable.

We know the health system does not want to pay for mass preventative treatment, and doctors know medication compliance is also a problem - both antibiotics and anti-malarials. High value individuals - no harm in that. WHO has a vested interest in keeping down genuine malaria deaths in dirt poor countries.

I think a better question to ask is does HCQ extend non-positive transmissions/ impact on testing. I think they knoiw the answer to that one.
 

Pushka

Enthusiast
Joined
Jan 26, 2011
Messages
18,656
Flights
My Map
Which of the 3 strains by four categories, then by age groups?
It is accepted there are 3 strains I think we know HCQ is no good for severe/ICU levels, and at that level immnosuppression is the go. Why do a study before a risk/reward cost benefit analysis has been done? In nursing homes - that seems reasonable.

We know the health system does not want to pay for mass preventative treatment, and doctors know medication compliance is also a problem - both antibiotics and anti-malarials. High value individuals - no harm in that. WHO has a vested interest in keeping down genuine malaria deaths in dirt poor countries.

I think a better question to ask is does HCQ extend non-positive transmissions/ impact on testing. I think they knoiw the answer to that one.
I think it might actually assist in reducing the immune response if given as prophylaxis and not as an active treatment where it's too late to take effect. Takes about 2 months for auto immune issues.
 
Top